Aura Biosciences, Inc. (AURA)
Nasdaq: AURA · Biological Products, (No Diagnostic Substances) · Boston, MA · filing with the SEC since 2010
Who owns Aura Biosciences, Inc.
As filed with the SECHolders of 5% or more
6
Chen Yu holds 9.9% of Common Stock, par value $0.00001 per share, as its SCHEDULE 13G filed May 12, 2026 says.
Directors and officers
15
report now, of 22 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Chen Yu
SCHEDULE 13G · filed May 12, 2026 · Common Stock, par value $0.00001 per share
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed Aug 12, 2026 · Common Stock, par value $0.00001 per share
Suvretta Capital Management, LLC
SCHEDULE 13G/A · filed Aug 13, 2025 · Common Stock, par value $0.00001 per share · 6.1% in Apr 11, 2025
Frazier Life Sciences Public Fund, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.00001 par value per share · 6.3% in Feb 13, 2026
ForGrowth III PA B.V.
SCHEDULE 13G · filed Oct 1, 2026 · Common Stock, par value $0.00001 per share
Blackrock, Inc.
SCHEDULE 13G · filed Oct 27, 2026 · Common Stock · 4.4% in Jul 27, 2026
Long Focus Capital Management, LLC
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock · reported falling below 5%, from 6.6% in May 15, 2025
Rajesh Parekh, Ph.D.
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.00001 per share · reported falling below 5%
Matrix Capital Management Company LP
SCHEDULE 13D/A · filed May 11, 2026 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 11.2% in May 19, 2025
Eventide Asset Management, LLC
SCHEDULE 13G/A · filed May 14, 2025 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 0% in May 13, 2025
What AURA reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
L I C O R Inc
An entity · legal entity · owns, named in the 10-K filed Mar 30, 2026
3 subsidiaries in 3 countries, from the list filed with the 10-K filed Mar 24, 2025.
Insider tradesForm 4
13sales
0purchases
0sales on a scheduled plan
6people selling
$1.0Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 28 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Matrix Capital Management Company, LP | 10% owner | 1 | $39.0M | 0 | 0 | $0 |
| De Los Pinos Elisabet | President and Chief Executive Officer | 3 | $400,000 | 0 | 0 | $0 |
| Hopkins Janet Jill | Chief Medical Officer | 2 | $200,000 | 0 | 0 | $0 |
| Plavsic Mark | Chief Technology Officer | 2 | $200,000 | 0 | 0 | $0 |
| Gibney Anthony S | Chief Financial and Business Officer. | 1 | $100,000 | 0 | 0 | $0 |
| Kilroy Conor | Chief Legal Officer and Secretary | 2 | $100,000 | 0 | 0 | $0 |
| Elazzouzi Amy | SVP, Finance & PAO | 3 | $100,000 | 0 | 0 | $0 |